Novartis taps into gene editing for next generation drugs

January 7, 2015 11:16 AM

3 0

Novartis taps into gene editing for next generation drugs

LONDON (Reuters) - Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.

The tie-ups with unlisted Intellia Therapeutics and Caribou Biosciences show the Swiss drugmaker's confidence in the potential of so-called CRISPR technology, both for making new medicines and as a research tool.

Read more

To category page

Loading...